SCHEMBL14686541

SCHEMBL14686541

O=C(Cc1ccccc1C(F)(F)F)N1CCC(c2cc(-c3ccc(F)cc3)nn2-c2ncccn2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 6/20 1.00
▸ RBP4 P02753 3/20 0.48
▸ SYK P43405 2/20 0.46
▸ MAPK13 O15264 1/20 0.42
▸ MAPK12 P53778 1/20 0.42
▸ MAPK11 Q15759 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ LMNA P02545 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ GRM5 P41594 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ SCD O00767 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14701329 0.92 PRCP (0.86) PRCPRBP4SYKCNR1GRM5
SCHEMBL12184064 0.91 PRCP (0.83) PRCPRBP4SYKMAPK13MAPK12
SCHEMBL17826599 0.89 PRCP (0.80) PRCPCNR1LMNAALOX15TSHR
SCHEMBL14686464 0.86 PRCP (0.76) PRCPSYKLMNAALOX15TSHR
SCHEMBL14686430 0.86 PRCP (0.76) PRCPLMNATSHRPOLB
SCHEMBL14749287 0.84 PRCP (0.72) PRCPRBP4SYKCNR1
SCHEMBL12185519 0.83 PRCP (0.71) PRCPRBP4SYKCNR1LMNA
SCHEMBL12185618 0.81 PRCP (0.69) PRCPRBP4SYKCNR1POLB
SCHEMBL14749338 0.79 PRCP (0.65) PRCPSYK
SCHEMBL14749335 0.78 PRCP (0.64) PRCPPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2568812-B1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-26 — — EP disclosed
EP-2568812-B1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-26 — — EP disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP PRCP 1/4885RBP4 354/4885SYK 4846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback